Details of the Drug

General Information of Drug (ID: DM7YBGH)

Drug Name
AL001
Synonyms Latozinemab
Indication
Disease Entry ICD 11 Status REF
Frontotemporal dementia 6D83 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DO57XC

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sortilin (SORT1) TTRX9AV SORT_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04374136) A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene. U.S.National Institutes of Health.
2 Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia. J Transl Med. 2023 Jun 15;21(1):387.